Opendata, web and dolomites

MIRASYS

The diagnostic potential of miRNAs for early diagnosis of Systemic Sclerosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MIRASYS project word cloud

Explore the words cloud of the MIRASYS project. It provides you a very rough idea of what is the project "MIRASYS" about.

business    demonstrated    worldwide    disease    spin    consists    unknown    autoimmune    analysed    found    diagnostic    validate    monitoring    consolidated    professionals    ip    elevated    mirna    fibrosis    prognostic    symptoms    setting    market    poc    subjects    commercialise    mirasys    precede    mirnas    team    sclerosis    off    positively    commercial    actionable    incorporate    burden    potent    disorder    formulate    organs    combination    company    160    prior    full    assay    plan    feasibility    correlates    operate    breakthrough    expression    grant    diagnosis    systemic    approximately    progression    connective    manifestations    freedom    models    impossible    life    skin    profiles    clinical    microrna    investors    ssc    complications    characterised    threatening    internal    stage    biomarkers    thoroughly    science    strategic    landscape    panel    accelerate    erc    tissue    boundaries    presented    position    diagnostics    patients    designed    onset    proprietary    commercialisation    strategy    detection   

Project "MIRASYS" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

Organization address
address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX
website: www.umcutrecht.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 149˙190 €
 EC max contribution 149˙190 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) coordinator 149˙190.00

Map

 Project objective

Systemic sclerosis (SSc) is a life-threatening autoimmune connective tissue disorder of unknown cause, characterised by fibrosis of the skin and internal organs. SSc affects approximately 160.000 patients worldwide and is associated with life-long burden of disease. Early detection of SSc is currently impossible as diagnosis is typically based on a combination of late-stage clinical symptoms. Current diagnostics, however, are based on late clinical manifestations. There is a need for actionable biomarkers for early-stage diagnosis and disease monitoring.

Based on proprietary ERC research specific microRNA (miRNA) profiles were found that positively correlates with clinical progression and complications of SSc. Its expression was elevated in subjects who demonstrated symptoms that can precede SSc onset by years. These findings provide strong support for the prognostic and diagnostic properties of the miRNA panel in SSc.

MIRASYS has been designed to accelerate the commercialisation of a panel of highly potent miRNAs that have breakthrough diagnostic potential in SSc. MIRASYS will be used to validate these findings by setting miRNA expression level boundaries for SSc development and to incorporate these in a diagnostic assay. MIRASYS will also assess the commercial feasibility of setting-up a dedicated spin-off company to commercialise the technology. The team has analysed the IP landscape for similar approaches for SSc and no prior art on the specific miRNAs was found. In the MIRASYS ERC PoC Grant, the team will further investigate the IP position and formulate a strong IP strategy including the steps towards full Freedom to Operate.

The MIRASYS team consists of experienced science and business professionals. The team has developed several business models which need to be assessed thoroughly through in-depth market research. The results need to be consolidated into a strong business plan that will be presented to investors and strategic investors.

 Publications

year authors and title journal last update
List of publications.
2017 Marzia Rossato, Alsya J. Affandi, Soley Thordardottir, Catharina G. K. Wichers, Marta Cossu, Jasper C. A. Broen, Frederique M. Moret, Lara Bossini-Castillo, Eleni Chouri, Lenny van Bon, Femke Wolters, Wioleta Marut, Maarten van der Kroef, Sandra Silva-Cardoso, Cornelis P. J. Bekker, Harry Dolstra, Jacob M. van Laar, Javier Martin, Joel A. G. van Roon, Kris A. Reedquist, Lorenzo Beretta, Timothy R.
Association of MicroRNA-618 Expression With Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis
published pages: 1891-1902, ISSN: 2326-5191, DOI: 10.1002/art.40163
Arthritis & Rheumatology 69/9 2019-07-26

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIRASYS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MIRASYS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

Neurovulnerability (2019)

Molecular mechanisms underlying selective neuronal death in motor neuron diseases

Read More